Ma XB, et al. - In diffuse large B-cell lymphoma (DLBCL), both CD5 and CD43 are expressed on the surface of B lymphocytes of definite phase and linked to adverse outcome, so researchers assessed the relationship between CD5 and CD43 expression and the prognostic value of CD5/CD43 coexpression in DLBCL. They analyzed 200 patients with DLBCL receiving standard chemotherapy with or without rituximab. As per findings, DLBCL patients with CD5/CD43 coexpression represent a specific subgroup with a significantly poor prognosis vs those expressing either marker alone.